AI Article Synopsis
- Carcinoid tumors are rare, slow-growing tumors with relatively good survival rates in their primary form, but metastatic carcinoid tumors lead to complications that increase morbidity and mortality.
- Cardiovascular manifestations are the most common cause of death in patients with metastatic carcinoid tumors, primarily due to biologically active substances produced by the tumor that affect heart function.
- The review aims to explore the spectrum of carcinoid heart diseases and their molecular biology to enhance understanding, develop targeted therapies, and improve early diagnosis, potentially reducing health risks associated with the disease.
Article Abstract
Carcinoid tumors (CT) are among the least studied tumors. It is a relatively rare and slow-growing tumor with good survival in its primary form. However, metastatic carcinoid tumor comes up with many different complications contributing to increased morbidity and mortality. Metastatic form of the disease has a wide spectrum of clinical manifestations and multisystem involvement including cardiovascular manifestations, neurological manifestations, and psychiatric manifestations and so on. In this review, we are centered towards the cardiovascular manifestations of the disease, which, by far, is one of the commonest causes of death in these patients. Being a neuroendocrine tumor, cardiovascular manifestations are mainly because of biologically active substances, produced by the tumor cells, remodeling the heart. Development of targeted therapies against carcinoid heart diseases is currently limited by lack of understanding of pathophysiology of the disease processes. In this review, we aim to figure out the spectrum of carcinoid heart diseases, along with the molecular biology of the changes going on, which, in turn, will not only pave a way to the development of targeted therapies but will also extend opportunities for molecular screening of the tumor and diagnosis at an early stage, thereby, reducing the morbidity and mortality.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681439 | PMC |
| http://dx.doi.org/10.1097/MD.0000000000036043 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[An unusual tricuspid regurgitation].
G Ital Cardiol (Rome)
January 2025
U.O. Cardiologia, Dipartimento di Specialità Medico-Chirurgiche, Scienze Radiologiche e Sanità Pubblica, Università degli Studi, Brescia.
Tricuspid regurgitation can be due to different causes and mechanisms. Among these, cardiac involvement in carcinoid disease is a rare cause of tricuspid valve disease with a peculiar echocardiographic aspect. We report the case of a 59-year-old woman, with no past medical history, who was recently found to have a heart murmur and signs of right heart failure.
View Article and Find Full Text PDFPleural carcinoid diagnosed via video-assisted thoracoscopy biopsies in a patient with recurrent unilateral pleural effusion at St. Francis hospital Nsambya: a case report.
J Med Case Rep
December 2024
RineCynth Advisory Limited, Kampala, Uganda.
Background: Pulmonary carcinoids are rare neuroendocrine tumors accounting for less than 1% of all lung cancers. They are classified into two subcategories; typical and atypical carcinoids with the latter tending to grow faster. Historically, open thoracotomy was the standard approach for pulmonary resection.
View Article and Find Full Text PDFThe Value of Repeat 5-HIAA Measurements as a Predictor of Carcinoid Heart Disease: A Prospective 5-Year Follow-Up Study in Patients with Small Intestinal Neuroendocrine Tumors.
Cancers (Basel)
November 2024
Endocrinology, Abdominal Center, Helsinki University Hospital and University of Helsinki, ENDO-ERN (European Reference Network on Rare Endocrine Conditions), 00280 Helsinki, Finland.
Small intestinal neuroendocrine tumors (SI-NETs) are characterized by carcinoid syndrome and carcinoid heart disease (CHD). The aim of the present study was to identify early risk markers for carcinoid heart disease and survival in a prospective median-term follow-up setting. We measured 5-HIAA and cumulative 5-HIAA exposure (Cum-5-HIAA) based on repeated measurements, proBNP, vascular function, hepatic tumor load, and transthoracic echocardiography (TTE) at baseline and during the median 5-year follow-up.
View Article and Find Full Text PDFBackground: Following the publication of international cardio-oncology (CO) imaging guidelines, standard echocardiographic monitoring parameters of left ventricular systolic function have been endorsed. Recommendations highlight that either two-dimensional (2D) or three-dimensional (3D) left ventricular ejection fraction (LVEF), alongside global longitudinal strain (GLS) should be routinely performed for surveillance of patients at risk of cancer therapy-related cardiac dysfunction (CTRCD). We studied the feasibility of 3D-LVEF, 2D-GLS and 2D-LVEF in a dedicated CO service.
View Article and Find Full Text PDFCarcinoid Heart Disease Associated with Primary Ovarian Carcinoid Tumor: A Rare Presentation.
Heart Views
October 2024
Department of Cardiology, University Hospitals, Leicester, UK.
Article Synopsis
- - Primary ovarian carcinoid tumors are extremely rare, accounting for less than 0.1% of ovarian cancers, and often present with symptoms like abdominal pain and bloating.
- - A 54-year-old woman experienced dyspnea and edema, which were initially misdiagnosed as heart failure without classic carcinoid syndrome symptoms, but further tests indicated carcinoid disease.
- - Surgical treatment included valve repair and removal of reproductive organs, underscoring the importance of prompt diagnosis and intervention for managing complications like carcinoid heart disease.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!